Company Filing History:
Years Active: 2014-2017
Title: Neville James McLean: Innovator in PI3K Inhibitor Compounds
Introduction
Neville James McLean is a notable inventor based in Harlow, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of PI3K inhibitor compounds. With a total of 3 patents to his name, McLean's work focuses on innovative methods for treating various pathological conditions.
Latest Patents
McLean's latest patents include groundbreaking research on tricyclic PI3K inhibitor compounds and methods of use. These compounds exhibit anti-cancer activity, anti-inflammatory activity, and immunoregulatory properties. Specifically, the compounds of Formula I are designed to modulate or inhibit PI3 kinase activity. The methods outlined in his patents describe the use of these compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells and associated pathological conditions. Additionally, he has developed dioxino- and oxazin-[2,3-D]pyrimidine PI3K inhibitor compounds, which also demonstrate similar therapeutic properties.
Career Highlights
Throughout his career, McLean has worked with prominent companies in the pharmaceutical industry, including Genentech, Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has contributed to his expertise in the development of innovative therapeutic compounds.
Collaborations
Some of McLean's notable coworkers include Robert Andrew Heald and Jennafer Dotson. Their collaborative efforts have further advanced the research and development of PI3K inhibitors.
Conclusion
Neville James McLean is a distinguished inventor whose work in PI3K inhibitor compounds has the potential to impact the treatment of various diseases. His innovative approaches and collaborations highlight the importance of research in advancing medical science.